



B15

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, C07K 16/28, A61K 38/13, A61P 37/06 // (A61K 39/395, 38:13)		A1	(11) International Publication Number: WO 00/30679
			(43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/EP99/08988		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	
(22) International Filing Date: 22 November 1999 (22.11.99)			
(30) Priority Data: 9825632.4 23 November 1998 (23.11.98) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).			
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): FEUTREN, Gilles [FR/FR]; 31, rue du Belvédère, F-68100 Mulhouse (FR). HOWELL, Richard, K. [GB/CH]; Binningerstrasse 36, CH-4123 Allschwil (CH). MARBACH, Peter [CH/CH]; Rämelsstrasse 2, CH-4106 Therwil (CH). ROBERTS, Andrew [GB/GB]; 56 Blakes Farm Road, Southwater, West Sussex RH13 7GQ (GB). SCHREIER, Max, H. [DE/CH]; Oberwilerstrasse 50, CH-4054 Basel (CH). SCHULZ, Manfred [DE/DE]; Kolpingstrasse 28, D-79539 Lörrach (DE).		Published With international search report.	
(54) Title: CD25 BINDING MOLECULES FOR USE IN THE TREATMENT OF MANIFESTATIONS OF REJECTION IN TRANSPLANTATION			
(57) Abstract			
Administration of monoclonal antibodies specific for IL-2R to xenograft recipients, or long-term to immunosuppression-intolerant or-non-compliant patients over a period of time beyond the very early phase of organ transplantation, prevents transplant rejection.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Moongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CD25 binding molecules for use in the treatment of manifestations of rejection in transplantation

The invention is directed to the use of a CD25 binding molecule in the treatment of rejection in transplantation.

A serious problem following transplantation is associated with the fact that transplant patients receive a long-term immunosuppression, a so-called triple therapy composed of a calcineurin inhibitor like cyclosporin A or FK-506, a steroid and a concomitant immunosuppressant like azathioprine, mycophenolic acid, mycophenolate mofetil, a 15-deoxyspergualine, rapamycin or 40-O-(2-hydroxy)ethyl-rapamycin (RAD001). Some patients, in particular juvenile and adolescent patients, however, have difficulties in accepting the constraints of the treatment and show poor compliance. Others are intolerant to calcineurin inhibitors, and develop severe adverse side effects, e.g. renal disfunction, hirsutism, gingival hyperplasia and hypertension. As a result many patients decrease the dosage of the respective medication or stop it entirely. The result for both groups is an unsatisfactory level of immunosuppression with the threat of losing the transplant.

Monoclonal antibodies specific for the interleukin-2 receptor (IL-2R) are currently used for the so-called induction treatment, i.e. as prophylactic short-term immunosuppressants for single or multiple administration in the very early phase following transplantation, e.g. shortly before the transplantation and up to 3 months after transplantation.

Surprisingly, it has now been discovered that the administration of monoclonal antibodies specific for IL-2R over a period of time beyond the very early phase following transplantation to immunosuppression-intolerant or -non-compliant patients decreases the risk of transplant rejection resulting from a reduced level of immunosuppression, especially from reduced levels of calcineurin inhibition.

A period of time beyond the very early phase following transplantation is that period of time that begins some weeks, months or even years after transplantation depending on the nature of the side effects and on the patient's perception of the severity of the side effects, and may last for the rest of life of the transplant recipient. The reduction in calcineurin inhibi-

tor dose may occur in the first weeks because of immediate side effects, or, especially in paediatric patients, much later as the patient matures and becomes aware of cosmetic changes that can effect social behaviour.

Compounds suitable for the purposes of this invention include monoclonal antibodies specific for the α subunit of IL-2R (\cong 55 kDa), CD25, i.e. IL-2R α , e.g. a humanized antibody, e.g. a humanized antibody having two pairs of light/heavy chain dimers, wherein each chain comprises complementarity determining regions (CDR's) and human-like framework regions, wherein the CDR's are from different immunoglobulin molecules than the framework regions, or a chimeric antibody, e.g. a chimeric antibody which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His, said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly, and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Tyr-Phe-Asp-Phe; or direct equivalents thereof.

Humanized antibodies have been disclosed together with processes for their preparation in WO 90/07861, the content of which is incorporated herein by reference. These antibodies have, on the basis of observed activity in e.g. a test to determine antibody-dependent cell mediated cytotoxicity, been found to be useful as immunosuppressant for the prevention of graft rejection. An individual antibody of WO 90/07861, daclizumab, is multiply administered to transplant patients during the first three months following transplantation.

Chimeric antibodies have been disclosed together with processes for their preparation in EP 449,769, the content of which is incorporated herein by reference. These antibodies have, on the basis of observed activity in e.g. a test to determine cell proliferation, been found to be useful as immunosuppressant for the prevention of graft rejection. An individual antibody of EP 449,769, basiliximab, is twice administered to transplant patients on the day of transplantation and 4 days later.

Individual antibodies suitable for use in accordance with the present invention are the humanized antibody daclizumab and the chimeric antibody basiliximab.

A preferred compound for use in accordance with the present invention is basiliximab which is commercially available as SIMULECT® from Novartis.

In accordance with the particular findings of the present invention, there is provided:

1. A method of preventing or treating transplant rejection in a recipient of organ, tissue or unmodified or modified cell transplant, e.g. heart, lung, combined heart-lung, trachea, liver, kidney, pancreas, Islet cell, bowel, e.g. small bowel, skin, muscles or limb, bone marrow, oesophagus, cornea or nervous tissue transplant, which method comprises long-term administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, over a period of time beyond the very early phase following transplantation.

In a preferred embodiment the invention provides

2. A method of preventing or treating rejection in an immunosuppression-intolerant or -non-compliant recipient of organ, tissue or unmodified or modified cell transplant, e.g. heart, lung, combined heart-lung, trachea, liver, kidney, pancreas, Islet cell, bowel, e.g. small bowel, skin, muscles or limb, bone marrow, oesophagus, cornea or nervous tissue transplant, which method comprises long-term administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, over a period of time beyond the very early phase following transplantation.

The organ, tissue or unmodified or modified cell transplant may be of human (allotransplantation) or non-human, e.g. pig, (xenotransplantation) origin.

In further embodiments, the present invention provides:

3.1 A method of preventing or treating xenotransplant rejection in a recipient of an organ, tissue or unmodified or modified cell xenotransplant, e.g. heart, lung, combined heart-lung, trachea, liver, kidney, pancreas, Islet cell, bowel, e.g. small bowel, skin, muscles or limb, bone marrow, oesophagus, cornea or nervous tissue transplant which method comprises administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab.

3.2 A method of preventing or treating rejection in a recipient of an organ, tissue or unmodified or modified cell xenotransplant, e.g. heart, lung, combined heart-lung, trachea, liver, kidney, pancreas, islet cell, bowel, e.g. small bowel, skin, muscles or limb, bone marrow, oesophagus, cornea or nervous tissue transplant, which method comprises administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab.

As alternative to the above the present invention also provides:

4. A monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, for use in any method as defined under 1 to 3 above; or
5. A monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, for use in the preparation of a pharmaceutical composition for use in any method as defined under 1 to 3 above; or
6. A pharmaceutical composition for use in any method as defined under 1 to 3 above comprising a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, together with one or more pharmaceutically acceptable diluents or carriers therefor.

Utility of a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, in preventing transplant rejection as hereinabove specified, may be demonstrated in clinic where e.g. the transplanted organ, tissue or unmodified or modified cell transplant may be submitted to regular controls, e.g. to biopsy controls or ultrasound scanning. Daclizumab may be useful as rescue treatment when the first symptoms of rejection occur.

I. Partial replacement of calcineurin inhibitor by monoclonal antibody specific for IL-2R

30 patients intolerant to cyclosporine A are randomized to one of two treatment groups; those receiving a maintenance dose of Sandimmun Neoral[®] sufficient to achieve cyclosporine A trough levels above 200 ng/ml and those receiving a maintenance dose of Sandimmun Neoral[®] sufficient to achieve cyclosporine A trough levels above 100 ng/ml + a monoclonal antibody specific for IL-2R, e.g. basiliximab or daclizumab. The patients are

also on stable doses of prednisone. The monoclonal antibody specific for IL-2R is administered intravenously at a dose of 40 mg every month.

During the treatment, markers of rejection, e.g. rise in creatinine or decreased GFR (for renal transplant recipients) or rising liver transaminases (for liver transplant recipients), and of calcineurin inhibitor intolerance, e.g. renal dysfunction, hirsutism, hypertension, gingival and hyperplasia, are monitored.

When a calcineurin inhibitor intolerant patient receives a monoclonal antibody specific for IL-2R, e.g. a humanized or chimeric monoclonal antibody specific for IL-2R, especially basiliximab or daclizumab, and a reduced dosage of a calcineurin inhibitor, e.g. cyclosporine A, side effects of the calcineurin inhibitor are reduced. Patients receiving the lower dose of Sandimmun Neoral® + a monoclonal antibody specific for IL-2R compared with those receiving the higher dose of Sandimmun Neoral® and no monoclonal antibody specific for IL-2R show a satisfactory level of immunosuppression. The monoclonal antibody specific for IL-2R, e.g. basiliximab or daclizumab is effective when administered at a dose of 40 mg every month.

The beneficial effects of a monoclonal antibody specific for IL-2R, e.g. basiliximab or daclizumab, in xenotransplantation may be tested clinically.

The use of a monoclonal antibody specific for IL-2R according to the invention results in a better outcome than the as yet available therapies.

The appropriate dosage will, of course, vary depending upon, for example, the particular molecule to be employed, the host, the mode of administration and the severity of the condition being treated and the effects obtained. Satisfactory results are generally indicated to be obtained at dosages in the range of from about 0.1 mg to about 500 mg, e.g. of from 10 mg to 150 mg, especially 40 mg or 20 mg.

For preventing or treating rejection in an immunosuppression-intolerant or -non-compliant recipient of organ, tissue or unmodified or modified cell transplant, administration of a dose in the range of from 10 to 150 mg, especially 40 mg, may be on a weekly or monthly basis, for example every week, every two, three, four, five, six, seven or eight weeks, regularly or irregularly, as required.

An exemplary dosing regimen for preventing or treating rejection in an immunosuppression-intolerant or -non-compliant recipient of organ, tissue or unmodified or modified cell transplant beyond the very early phase following transplantation, is long-term monthly intravenous administration of 40 mg.

For preventing or treating rejection in a xenograft transplantation recipient, administration of a dose in the range of from 10 to 150 mg, especially 20 mg, may be within a day prior to transplantation followed by a single dose in the range of from 10 to 150 mg, especially 20 mg, within a week following transplantation or by one to 10 doses in the range of from 10 to 150 mg, especially 20 mg, for up to 10 weeks following transplantation; optionally followed by administration as often as indicated on a weekly or monthly basis, for example a dose in the range of from 10 to 150 mg, especially 40 mg, may be administered every week, every two, three, four, five, six, seven or eight weeks, regularly or irregularly, as required.

An exemplary dosing regimen for preventing rejection in a xenograft transplantation recipient is intravenous administration of 20 mg two hours prior to transplantation and 20 mg 4 days later; or 20 mg two hours prior to transplantation, 20 mg 4 days later, followed by monthly intravenous administration of 40 mg. Another exemplary dosing regimen for preventing rejection in a xenograft transplantation recipient is intravenous administration of 5 times 1 mg/kg body weight over 8 weeks; or intravenous administration of 1 mg/kg body weight every 10 days; or 5 times 1 mg/kg body weight over 8 weeks, followed by monthly intravenous administration of 2 mg/kg body weight.

Pharmaceutical compositions of the invention may be manufactured in a conventional manner as described, e.g. in EP 449769 or WO 90/07861. The composition may e.g. be prepared for storage as lyophilized powder in a vial. The solution for parenteral administration may conveniently be prepared shortly before administration.

The monoclonal antibodies specific for IL-2R may be administered together with other drugs in immunomodulating regimens or other anti-inflammatory agents. The monoclonal antibodies specific for IL-2R may be used in combination with cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, RAD001, rapamycin etc.; corticosteroids; cyclophosphamide; azathioprine; metho-

trexate; brequinar; leflunomide; mizoribine; mycophenolic acid; mycophenolate mofetil; 15-deoxyspergualine; other immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD28, B7, CD40, CD45, or CD58 or their ligands; or other immunomodulatory compounds, e.g. CTLA4Ig. Murine monoclonal antibodies suitable for use together with the monoclonal antibody are described in EP 449,769.

Dosages of the co-administered immunosuppressant or immunomodulatory compounds will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a cyclosporin, on the specific drug employed, on the condition being treated, and so forth. In accordance with the foregoing the present invention provides in a yet further aspect:

7. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a monoclonal antibody specific for IL-2R and a second drug substance, said second drug substance being an immunosuppressant or immunomodulatory drug, e.g. as indicated above.

If the monoclonal antibody is co-administered with a further drug substance both may be packaged separately within the same container, with instructions for mixing or concomitant administration. Examples of kits include for example a multi-barrelled syringe or a twin pack containing separate unit dose forms.

Investigations so far indicate that the administration of the monoclonal antibody is free from unacceptable side-effects at the dosage levels employed. Particularly the preferred one, basiliximab, is safe, approved by the Federal Drug Administration (FDA) of the United States and is commercially available.

Claims

1. A method of preventing or treating transplant rejection in a recipient of organ, tissue or unmodified or modified cell transplant, which method comprises long-term administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, over a period of time beyond the very early phase following transplantation.
2. A method of preventing or treating rejection in an immunosuppression-intolerant or -non-compliant recipient of organ, tissue or unmodified or modified cell transplant, which method comprises long-term administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R, over a period of time beyond the very early phase following transplantation.
3. A method of preventing or treating xenotransplant rejection in a recipient of an organ, tissue or unmodified or modified cell xenotransplant, which method comprises administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R.
4. A method of preventing or treating rejection in a recipient of an organ, tissue or unmodified or modified cell xenotransplant, which method comprises administering to said recipient an effective amount of a monoclonal antibody specific for IL-2R.
5. A monoclonal antibody specific for IL-2R for use in a method according to any of claims 1 to 4.
6. A monoclonal antibody specific for IL-2R for use in the preparation of a pharmaceutical composition for use in a method according to any of claims 1 to 4.
7. A pharmaceutical composition for use in a method according to any of claims 1 to 4 comprising a monoclonal antibody specific for IL-2R together with one or more pharmaceutically acceptable diluents or carriers therefor.
8. A method according to any of claims 1 to 4 comprising co-administration of a therapeutically effective amount of a monoclonal antibody specific for IL-2R and a second drug sub-

stance, said second drug substance being an immunosuppressant or immunomodulatory drug, e.g. as indicated above.

PCT/EP 99/08988

IPC 7 A61K39/395 C07K16/28 A61K38/13 A61P37/06
 //(A61K39/395,38:13)

B. FIELDS SEARCHED

IPC 7 C07K

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13067 A (PROTEIN DESIGN LABS INC.) 2 April 1998 (1998-04-02) page 13, line 11 - line 19 claims	1,2,5-8
X	WO 93 11238 A (SUMITOMO PHARMACEUTICALS COMPANY, LTD.) 10 June 1993 (1993-06-10) page 5, line 13 -page 6, line 7 page 21, line 6 - line 11 claims	1,2,5-7
	-/-	

X Patent family members are listed in annex.

"&" document member of the same patent family

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/08988

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>F. VINCENTI ET AL.: "Interleukin-2-receptor blockade with daclizumab to prevent acute reection in renal transplantation." NEW ENGLAND JOURNAL OF MEDICINE, vol. 338, no. 3, 15 January 1998 (1998-01-15), pages 161-165, XP000876965 Boston, MA, USA abstract page 162, left-hand column, line 1 - line 7</p>	1-8
A	<p>WO 90 07861 A (PROTEIN DESIGN LABS, INC.) 26 July 1990 (1990-07-26) cited in the application the whole document</p>	1-8
A	<p>EP 0 449 769 A (SANDOZ LTD. ET AL.) 2 October 1991 (1991-10-02) cited in the application the whole document</p>	1-8
A	<p>J. KOVARIK ET AL.: "Disposition and immunodynamics of basiliximab in liver allograft recipients." CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 64, no. 1, July 1998 (1998-07), pages 66-72, XP000876964 St. Louis, MO, USA abstract page 67, right-hand column, line 1 -page 68, left-hand column, line 9</p>	1-8
A	<p>P. AMLOT ET AL.: "Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation." TRANSPLANTATION, vol. 60, no. 7, 15 October 1995 (1995-10-15), pages 748-756, XP000876958 Baltimore, MD, USA abstract</p>	1-8
A	<p>K. YASUDA ET AL.: "Prolongation of allograft survival by administration of mAb specific for the three subunits of IL-2 receptor." INTERNATIONAL IMMUNOLOGY, vol. 10, no. 5, May 1998 (1998-05), pages 561-567, XP000876961 Oxford, GB abstract</p>	1-8

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/08988

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>L. WISEMAN ET AL.: "Daclizumab. A review of its use in the prevention of acute rejection in renal transplant recipients." DRUGS, vol. 58, no. 6, December 1999 (1999-12), pages 1029-1042, XP000876955 Sydney, Australia page 1032, line 10 - line 16 page 1039, left-hand column, line 11 -right-hand column, line 11</p>	1-8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/08988

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-4 and 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08988

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9813067	A	02-04-1998	AU 4494197 A EP 0932415 A	17-04-1998 04-08-1999
WO 9311238	A	10-06-1993	JP 5244982 A AT 180511 T DE 69229278 D DE 69229278 T EP 0616641 A US 5886152 A	24-09-1993 15-06-1999 01-07-1999 05-01-2000 28-09-1994 23-03-1999
WO 9007861	A	26-07-1990	AT 133452 T AT 183753 T AU 647383 B AU 5153290 A BG 61095 B CA 2006865 A CN 1043875 A DD 296964 A DE 68925536 D DE 68925536 T DE 68929061 D DK 119191 A EP 0451216 A EP 0682040 A EP 0939127 A ES 2081974 T HR 920500 A HU 9500236 A JP 11004694 A JP 2828340 B LU 90411 A MC 2146 A NO 912385 A NZ 231984 A PT 92758 A,B SI 8912489 A US 5693761 A US 5585089 A US 5693762 A US 5530101 A YU 248989 A ZA 8909956 A	15-02-1996 15-09-1999 24-03-1994 13-08-1990 31-10-1996 28-06-1990 18-07-1990 19-12-1991 07-03-1996 20-06-1996 30-09-1999 19-06-1991 16-10-1991 15-11-1995 01-09-1999 16-03-1996 30-04-1996 28-09-1995 12-01-1999 25-11-1998 02-09-1999 18-02-1992 19-06-1991 24-06-1997 29-06-1990 28-02-1999 02-12-1997 17-12-1996 02-12-1997 25-06-1996 31-10-1991 31-10-1990
EP 449769	A	02-10-1991	AT 98655 T AU 635401 B AU 7290991 A CA 2038279 A,C CY 1977 A DE 69100768 D DE 69100768 T DK 449769 T ES 2061216 T FI 911275 A FI 981799 A HK 53797 A HU 60768 A HU 9500213 A IE 65062 B	15-01-1994 18-03-1993 19-09-1991 17-09-1991 05-09-1997 27-01-1994 11-05-1994 21-02-1994 01-12-1994 17-09-1991 21-08-1998 02-05-1997 28-10-1992 28-12-1995 04-10-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08988

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 449769 A		JP 2585475 B	26-02-1997
		JP 4316600 A	06-11-1992
		LU 90383 A	07-06-1999
		NZ 237434 A	26-08-1992
		PL 170321 B	29-11-1996
		PT 97034 A,B	31-10-1991
		ZA 9101947 A	25-11-1992